(Q37600406)

21 August 2017

1 reference

title

Future gazing in the management of multiply drug-resistant Gram-positive infection (English)

1 reference

21 August 2017

main subject

gram-positive bacteria

0 references

1

Mark H Wilcox

1 reference

21 August 2017

publication date

1 September 2009

1 reference

21 August 2017

1 reference

21 August 2017

volume

59 Suppl 1

1 reference

21 August 2017

page(s)

S75-80

1 reference

Drotrecogin Alfa (activated) Improves In-hospital and 90-day Survival in Patients With Severe Sepsis and Community-acquired Pneumoni

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960010-4

7 January 2021

Antibiotic cycling or rotation: a systematic review of the evidence of efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960010-4

7 January 2021

Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960010-4

7 January 2021

Delayed development of linezolid resistance in Staphylococcus aureus following exposure to low levels of antimicrobial agents

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960010-4

7 January 2021

Correlation between Reduced Daptomycin Susceptibility and Vancomycin Resistance in Vancomycin-Intermediate Staphylococcus aureus.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960010-4

7 January 2021

Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960010-4

7 January 2021

Does linezolid cause lactic acidosis by inhibiting mitochondrial protein synthesis?

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960010-4

7 January 2021

Inhibition of mammalian mitochondrial protein synthesis by oxazolidinones

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960010-4

7 January 2021

The scientific basis for using surveillance and risk factor data to reduce nosocomial infection rates.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960010-4

7 January 2021

A systematic review of the evidence for interventions for the prevention and control of meticillin-resistant Staphylococcus aureus (1996-2004): report to the Joint MRSA Working Party (Subgroup A).

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960010-4

7 January 2021

Evaluation of rapid screening and pre-emptive contact isolation for detecting and controlling methicillin-resistant Staphylococcus aureus in critical care: an interventional cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960010-4

7 January 2021

Impact of rapid screening tests on acquisition of meticillin resistant Staphylococcus aureus: cluster randomised crossover trial

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960010-4

7 January 2021

Universal screening for methicillin-resistant Staphylococcus aureus at hospital admission and nosocomial infection in surgical patients

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960010-4

7 January 2021

Universal surveillance for methicillin-resistant Staphylococcus aureus in 3 affiliated hospitals.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960010-4

7 January 2021

Use of perioperative mupirocin to prevent methicillin-resistant Staphylococcus aureus (MRSA) orthopaedic surgical site infections

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960010-4

7 January 2021

Intranasal mupirocin reduces sternal wound infection after open heart surgery in diabetics and nondiabetics

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960010-4

7 January 2021

Surgical site infections in orthopedic surgery: the effect of mupirocin nasal ointment in a double-blind, randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960010-4

7 January 2021

Surveillance for mupirocin resistance following introduction of routine peri-operative prophylaxis with nasal mupirocin

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960010-4

7 January 2021

Development of mupirocin resistance among methicillin-resistant Staphylococcus aureus after widespread use of nasal mupirocin ointment

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960010-4

7 January 2021

Activity of retapamulin (SB-275833), a novel pleuromutilin, against selected resistant gram-positive cocci

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960010-4

7 January 2021

Antibiotic prescribing as a risk factor for MRSA.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960010-4

7 January 2021

Fluoroquinolone use and methicillin-resistant Staphylococcus aureus isolation rates in hospitalized patients: a quasi experimental study

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960010-4

7 January 2021

Pharmacokinetics and tissue penetration of linezolid following multiple oral doses

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960010-4

7 January 2021

Linezolid versus teicoplanin in the treatment of Gram-positive infections in the critically ill: a randomized, double-blind, multicentre study.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2809%2960010-4

7 January 2021

10.1016/S0163-4453(09)60010-4

Identifiers

DOI

1 reference

21 August 2017

1 reference